Invention Application
- Patent Title: METHOD FOR PREDICTING OCCURRENCE OF IMMUNE-RELATED ADVERSE EVENTS INDUCED BY HLA TYPE-BASED CANCER IMMUNOTHERAPY AGENT
-
Application No.: US18730595Application Date: 2023-01-20
-
Publication No.: US20250101516A1Publication Date: 2025-03-27
- Inventor: Sook Ryun PARK , Jung Kyoon CHOI , Jinhyeon AN , Changhwan SUNG
- Applicant: THE ASAN FOUNDATION , UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION , KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
- Applicant Address: KR Seoul; KR Ulsan; KR Daejeon
- Assignee: THE ASAN FOUNDATION,UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION,KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
- Current Assignee: THE ASAN FOUNDATION,UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION,KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
- Current Assignee Address: KR Seoul; KR Ulsan; KR Daejeon
- Priority: KR10-2022-0008310 20220120,KR10-2023-0008353 20230119
- International Application: PCT/KR2023/001077 WO 20230120
- Main IPC: C12Q1/6881
- IPC: C12Q1/6881
Abstract:
A method for predicting the occurrence of immune-related adverse events (irAEs) induced by an HLA type-based cancer immunotherapy agent. The method involves determining copy number variations (CNVs) of the HLA gene, such as HLA-B exon 2 deficiency, or HLA alleles such as HLA-B*35:01, HLA-B*40:02, HLA-B*54:01, or detecting an allele of an HLA gene selected from HLA-B*35:01, HLA-B*40:02, and HLA-B*54:01, in a biological sample isolated from a subject, and treating the cancer immunotherapy-induced irAE in the subject by administering to the subject a corticosteroid or immunosuppressant.
Information query
IPC分类:
